Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors

NCT02988817 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT02988817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02988817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Completed
Start date
November 23, 2016
Completion date
November 12, 2021
Enrollment
306 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, melanoma, non small cell lung cancer (nsclc), ovarian cancer, sarcoma, solid tumors, thyroid cancer